progress
smaller
prematur
infant
surviv
beyond
first
day
life
healthcareassoci
infect
hai
emerg
major
caus
morbid
late
mortal
neonat
intens
care
unit
nicu
effect
prevent
treatment
hai
nicu
requir
understand
distribut
pathogen
variou
patientrel
risk
factor
infect
role
medic
invas
procedur
predispos
occurr
lateonset
sepsi
defin
nation
institut
child
health
human
develop
neonat
research
network
nichd
nrn
bsi
occur
neonat
hour
age
lateonset
sepsi
common
low
birth
weight
vlbw
infant
g
hai
increas
hospit
length
stay
day
caus
death
beyond
week
age
lateonset
sepsi
occur
vlbw
infant
surviv
beyond
day
age
nichd
nrn
studi
similar
rate
report
neonat
network
canada
israel
institut
level
preval
lateonset
sepsi
vlbw
infant
vari
nicu
nichd
nrn
nicu
particip
canadian
neonat
network
data
nichd
nrn
confirm
risk
lateonset
sepsi
despit
advanc
medic
care
extrem
prematur
infant
infant
born
week
gestat
lateonset
sepsi
rate
lateonset
sepsi
strongli
invers
associ
birth
weight
gestat
age
decreas
among
neonat
gestat
age
less
week
among
infant
born
week
gestat
consequ
institut
care
extrem
low
birth
weight
elbw
infant
higher
rate
manag
practic
particularli
concern
use
mainten
care
central
venou
cathet
cvc
peripher
insert
central
cathet
picc
impact
rate
infect
case
lateonset
sepsi
neonat
associ
central
cathet
ie
cvc
picc
refer
central
lineassoci
bloodstream
infect
clabsi
center
diseas
control
prevent
cdc
nation
healthcar
safeti
network
nhsn
definit
clabsi
includ
isol
pathogen
one
blood
cultur
skin
commens
two
blood
cultur
one
clinic
sign
infect
eg
apnea
bradycardia
temperatur
instabl
relat
infect
anoth
site
presenc
cvc
time
blood
cultur
obtain
within
hour
develop
infect
urinari
catheterassoci
uti
cauti
account
highest
risk
hai
found
patient
birth
weight
less
g
rel
risk
examin
pair
blood
urin
cultur
vlbw
infant
suspect
lateonset
sepsi
tamim
colleagu
detect
uti
among
vlbw
infant
uti
neg
blood
cultur
phillip
karlowicz
report
case
seri
uti
among
nicu
patient
primarili
document
specimen
obtain
urethr
catheter
lateonset
sepsi
suspect
simultan
bsi
pathogen
detect
case
candida
uti
case
bacteri
uti
vlbw
infant
uti
bsi
practic
obtain
urin
cultur
steril
urethr
catheter
suprapub
aspir
lateonset
sepsi
suspect
difficult
diagnosi
healthcareassoci
pneumonia
patient
popul
particularli
nicu
popul
new
definit
cdc
nhsn
attempt
provid
reproduc
criteria
surveil
classifi
pneumonia
three
specif
type
clinic
defin
pneumonia
laboratori
find
pneumonia
immunocompromis
patient
infant
children
usual
fall
categori
diagnosi
ventilatorassoci
pneumonia
vap
especi
difficult
neonat
noninfecti
condit
respiratori
distress
syndrom
bronchopulmonari
dysplasia
common
frequent
caus
radiolog
abnorm
nhsn
publish
specif
guidelin
adapt
infant
younger
year
age
specif
prematur
infant
new
benchmark
data
becom
avail
nhsn
highest
incid
vap
ie
case
per
ventil
day
occur
among
infant
median
birth
weight
less
gram
investig
attempt
establish
reproduc
criteria
vap
specif
neonat
popul
cordero
cowork
show
find
purul
tracheal
aspir
fluid
posit
tracheal
cultur
mechan
ventil
neonat
absenc
worsen
clinic
radiolog
find
consist
clinic
insignific
tracheal
colon
vap
apisarnthanarak
colleagu
perform
prospect
cohort
studi
address
risk
factor
microbiolog
outcom
vap
neonat
definit
vap
requir
new
persist
radiolog
evid
focal
infiltr
hour
initi
mechan
ventil
treatment
antibiot
day
presum
vap
definit
mechan
ventil
vlbw
infant
develop
vap
rate
per
ventilatorday
gramneg
bacteria
isol
tracheal
aspir
vap
episod
case
polymicrobi
vap
develop
neonat
median
ventil
day
risk
vap
increas
everi
addit
week
infant
mechan
ventil
vap
strongli
associ
mortal
among
neonat
requir
nicu
care
day
periton
associ
intestin
perfor
seriou
hai
nicu
coat
associ
report
strike
differ
distribut
pathogen
associ
periton
infant
focal
intestin
perfor
fip
compar
infant
necrot
enterocol
nec
enterobacteriacea
found
nec
case
compar
fip
case
candida
speci
found
fip
case
nec
case
coagulaseneg
staphylococci
con
found
fip
case
nec
case
periton
fluid
cultur
posit
help
direct
antimicrobi
therapi
case
periton
fluid
cultur
obtain
neonat
intestin
perfor
regardless
caus
conjunct
common
healthi
term
newborn
studi
address
occurr
nicu
diagnosi
complic
conjunctiv
colon
especi
con
common
nicu
rate
hai
link
devic
use
clabsi
help
control
variat
manag
practic
institut
institut
prefer
unit
measur
infect
per
catheterday
nhsn
continu
recommend
clabsi
major
focu
surveil
prevent
effort
nicu
institut
provid
summari
data
clabsi
rate
differ
birth
weight
group
valu
extrem
nhsn
data
indic
problem
effect
infect
control
underreport
clabsi
event
respect
individu
nicu
encourag
monitor
compar
clabsi
rate
nhsn
data
updat
annual
usual
publish
decemb
data
clabsi
rate
nhsn
particip
level
iii
nicu
year
show
median
number
bsi
per
catheterday
infant
weigh
g
less
weigh
g
weigh
g
birth
percentil
bsi
per
catheterday
infant
weigh
g
less
weigh
g
weigh
g
birth
valu
repres
continu
declin
clabsi
devic
use
data
also
obtain
umbil
catheterassoci
bsi
period
reveal
low
rate
infect
weight
categori
coexist
endocard
infect
intravascular
thrombu
osteomyel
pyogen
arthriti
consid
bsi
persist
neonat
staphylococcu
aureu
common
caus
endocard
osteomyel
neonat
complic
uncommon
diagnosi
consid
multipl
blood
cultur
posit
neonat
cvc
recent
surveil
data
incid
lateonset
mening
nicu
consequ
consider
variat
exist
clinic
practic
concern
perform
lumbar
punctur
neonat
suspect
lateonset
sepsi
prospect
studi
vlbw
infant
surviv
day
lateonset
mening
occur
infant
repres
infant
lumbar
punctur
perform
compar
infant
without
septicemia
vlbw
infant
mening
like
seizur
vs
like
die
vs
one
third
infant
mening
blood
cultur
drawn
simultan
neg
mening
alter
durat
antibiot
therapi
affect
longterm
prognosi
complic
paramening
brain
abscess
vlbw
infant
suspect
lateonset
sepsi
lumbar
punctur
part
initi
diagnost
evalu
unless
critic
ill
toler
procedur
latter
case
lumbar
punctur
perform
clinic
stabil
achiev
uti
common
hai
adult
frequent
associ
indwel
urinari
cathet
seldom
use
vlbw
infant
consider
variat
perform
urin
cultur
analysi
lateonset
sepsi
suspect
urin
specimen
obtain
bag
collect
infant
notori
high
rate
contaminationup
recommend
suprapub
bladder
aspir
perform
less
commonli
risk
seriou
albeit
rare
complic
bowel
perfor
increas
pain
steril
urethr
catheter
perform
easili
experienc
nurs
even
elbw
infant
potenti
higher
rate
success
obtain
urin
compar
suprapub
bladder
aspir
although
prospect
studi
perform
uti
may
second
common
hai
nicu
report
preval
among
prematur
infant
rang
report
repres
typic
popul
nicu
current
retrospect
studi
report
rate
lateonset
uti
among
vlbw
infant
one
nicu
period
uti
common
elbw
infant
infant
birth
weight
g
prospect
studi
one
nicu
period
rate
hai
rate
uti
interventionassoci
infect
examin
occurr
rate
conjunct
nicu
vari
haa
colleagu
report
prospect
studi
couto
cowork
report
although
infant
birth
weight
includ
common
pathogen
enter
gramneg
bacilli
nonenter
flora
pseudomona
aeruginosa
also
occur
neonat
skin
infect
caus
aureu
clinic
manifest
includ
impetigo
cellul
soft
tissu
abscess
toxinmedi
diseas
staphylococc
scald
skin
toxic
shock
syndrom
methicillinresist
methicillinsuscept
aureu
mrsa
mssa
caus
similar
infect
carey
associ
report
incid
mssa
mrsa
among
elbw
g
infant
skin
infect
nicu
skin
infect
occur
elbw
cohort
p
aeruginosa
caus
ecthyma
gangrenosum
lesion
even
vlbw
elbw
infant
zygomycet
caus
progress
necrot
skin
lesion
neonat
without
gastrointestin
manifest
gramposit
organ
predomin
caus
lateonset
sepsi
nicu
case
gramneg
organ
case
fungi
case
also
import
across
mani
report
pathogen
caus
episod
con
candida
speci
aureu
enterobacteriacea
tabl
verylateonset
sepsi
vlo
becom
common
vlbw
infant
live
longer
ongo
need
intervent
vlo
defin
infect
day
life
organ
caus
lateonset
sepsi
also
caus
vlo
usual
pathogen
frequenc
pathogen
likelihood
certain
pathogen
caus
rapid
progress
sever
complic
death
ie
fulmin
sepsi
must
consid
choos
empir
therapi
karlowicz
colleagu
report
although
gramneg
organ
caus
bsi
seri
caus
fulmin
lateonset
bsi
gramneg
bacilli
p
aeruginosa
caus
fulmin
case
overal
casefat
rate
contrast
casefat
rate
less
con
similar
find
report
other
con
common
pathogen
caus
lateonset
sepsi
account
case
distinguish
true
bsi
pseudobacteremia
difficult
cdc
nhsn
defin
laboratoryconfirm
bloodstream
infect
lcbi
common
skin
contamin
flora
posit
blood
cultur
drawn
separ
occas
report
stoll
cowork
lateonset
sepsi
rate
con
would
fallen
lcbsi
includ
rate
similar
report
karlowicz
colleagu
substanti
declin
lateonset
con
bsi
past
decad
due
implement
sever
infect
prevent
initi
gramposit
organ
predomin
pathogen
vlo
although
aureu
enterococcu
speci
common
con
wynn
associ
found
infect
vlbw
infant
caus
gramposit
organ
follow
gramneg
bacilli
fungi
candida
speci
produc
highest
organismspecif
mortal
rate
cohort
follow
gramposit
cocci
highest
organismspecif
mortal
rate
attribut
aureu
follow
p
aeruginosa
similar
lateonset
sepsi
preval
pathogen
commun
healthcar
nicu
environ
select
pressur
antibiot
use
contribut
antibioticresist
infect
nicu
gramposit
bacteria
includ
hospitaland
communityassoci
mrsa
camrsa
vancomycinresist
enterococcu
faecium
seriou
problem
nicu
incid
camrsa
vari
wide
across
nicu
mortal
rate
mrsa
mssa
infect
remain
high
frequent
cathet
relat
gramneg
enter
organ
eg
extendedspectrum
e
coli
klebsiella
spp
ampc
enterobact
spp
enter
bacilli
multidrugresist
serratia
marcescen
leclercia
adecarboxylata
nonenter
organ
eg
p
aeruginosa
burkholderia
cepacia
chryseobacterium
meningosepticum
recent
highli
resist
acinetobact
spp
emerg
nicu
environ
mani
instanc
reservoir
contain
organ
exist
within
healthcar
environ
patient
expos
use
contamin
medic
equip
hand
caretak
includ
famili
member
former
often
result
breakdown
clean
procedur
use
nicu
hospit
environ
latter
result
ineffect
use
hand
hygien
molecular
fingerprint
organ
use
character
control
outbreak
control
nicu
outbreak
antibioticresist
organ
frequent
requir
vigor
applic
infect
control
procedur
eg
surveil
cultur
patient
staff
cohort
hand
hygien
educ
intervent
activ
educ
factor
predispos
infect
cdc
began
campaign
prevent
antimicrobi
resist
variou
healthcar
set
valuabl
method
appli
success
nicu
hai
caus
virus
uncommon
nicu
incid
patient
vulner
propens
virus
spread
patient
patient
impact
substanti
nicu
outbreak
caus
respiratori
syncyti
viru
rsv
parainfluenza
noroviru
sometim
concurr
attack
casefat
rate
pathogen
local
suscept
pattern
like
pathogen
empir
antibiot
regimen
effect
treat
gramneg
pathogen
particularli
p
aeruginosa
nonenter
flora
aminoglycosid
use
empir
treatment
possibl
gramneg
septicemia
choic
determin
antimicrobi
suscept
pattern
isol
nicu
thirdgener
cephalosporin
recommend
routin
empir
therapi
neonat
unless
knowledg
patient
flora
nicu
pattern
infect
specif
dictat
activ
p
aeruginosa
enterobacteriacea
routin
use
nicu
associ
emerg
cephalosporinresist
gramneg
bacilli
use
associ
increas
risk
candidemia
vlbw
neonat
ampicillin
may
consid
empir
treatment
possibl
gramposit
septicemia
especi
enterococcu
streptococcu
agalactia
common
pathogen
caus
lateonset
sepsi
nicu
mrsa
preval
commun
nicu
vancomycin
use
firstlin
therapi
mrsa
identifi
vancomycin
discontinu
promptli
mssa
identifi
nafcillin
therapeut
superior
vancomycin
con
sepsi
common
physician
advoc
broad
empir
use
vancomycin
creat
addit
problem
stoll
associ
found
alarm
vlbw
infant
nichd
nrn
treat
vancomycin
whether
con
bsi
hospit
infect
control
practic
advisori
committe
cdc
recommend
avoid
empir
vancomycin
therapi
patient
suspect
sepsi
prevent
emerg
spread
vancomycinresist
enterococci
karlowicz
cowork
show
avoid
empir
use
vancomycin
impact
low
rate
fulmin
con
sepsi
practic
begin
vancomycin
con
identifi
blood
cultur
prolong
durat
bsi
despit
ongo
educ
vancomycin
continu
commonli
use
drug
nicu
survey
use
inappropri
instanc
one
studi
applic
guidelin
vancomycin
use
decreas
neonat
vancomycin
exposur
per
patientday
reduct
per
patientday
reduct
two
nicu
chang
caus
infect
durat
bsi
incid
complic
attribut
death
retrospect
studi
infant
con
bsi
across
nicu
surviv
benefit
empir
therapi
vancomycin
versu
therapi
delay
day
first
posit
blood
cultur
retrospect
review
vlbw
infant
con
sepsi
posit
blood
cultur
differ
outcom
infant
treat
vancomycin
day
last
posit
blood
cultur
compar
longer
cours
infant
endocard
infect
thrombi
exclud
approach
requir
prospect
studi
promis
reduc
vancomycin
use
antibiot
stewardship
specif
nicu
remain
critic
prevent
spread
resist
bacteria
avoid
use
medic
unnecessarili
use
empir
antifung
therapi
vlbw
infant
high
risk
candidemia
standard
studi
suggest
empir
therapi
may
reduc
mortal
rate
improv
outcom
vlbw
infant
small
retrospect
studi
empir
antifung
treatment
given
critic
ill
neonat
g
addit
risk
factor
invas
candida
infect
receiv
vancomycin
thirdgener
cephalosporin
day
one
follow
risk
receipt
total
parenter
nutrit
mechan
ventil
postnat
corticosteroid
therapi
h
block
agent
mucocutan
candida
infect
candidarel
mortal
occur
patient
receiv
empir
amphotericin
b
compar
histor
control
decis
use
empir
antifung
agent
lateonset
sepsi
made
individu
basi
suggest
durat
therapi
hai
anatom
site
summar
tabl
durat
treatment
individu
patient
determin
virul
pathogen
time
take
followup
cultur
becom
neg
rapid
clinic
respons
time
neg
blood
cultur
remov
retent
cvc
adequ
drainag
purul
foci
rate
high
patient
asymptomat
diseas
lethal
attribut
cost
high
virus
introduc
nicu
famili
member
ill
healthcar
personnel
hcp
rsv
adenoviru
parainfluenza
infect
manifest
cough
congest
apnea
increas
oxygen
requir
respiratori
failur
parainfluenza
adenoviru
infect
manifest
epidem
conjunct
ophthalmolog
procedur
contribut
spread
coronaviru
infect
manifest
respiratori
decompens
abdomin
distent
fever
infect
enterovirus
manifest
neclik
sign
overwhelm
septicemia
rash
asept
mening
rotaviru
infect
manifest
diarrhea
frequent
wateri
term
infant
wherea
preterm
infant
often
bloodi
associ
abdomin
distent
intestin
dilat
clinic
featur
sepsi
neonat
nonspecif
common
clinic
featur
increas
apnea
bradycardia
gastrointestin
problem
ie
feed
intoler
abdomin
distent
bloodi
stool
need
respiratori
support
lethargi
hypotonia
predomin
laboratori
indic
abnorm
white
blood
cell
count
eg
leukocytosi
increas
immatur
white
blood
cell
neutropenia
unexplain
metabol
acidosi
hyperglycemia
unfortun
predict
valu
featur
low
best
posit
predict
valu
hypotens
abnorm
heart
rate
characterist
ie
reduc
variabl
transient
deceler
occur
earli
cours
neonat
sepsi
although
technolog
develop
calcul
heart
rate
characterist
index
hrci
griffin
colleagu
found
hrci
perform
similar
clinic
score
system
predict
sepsi
common
sign
clabsi
neonat
fever
respiratori
distress
patient
erythema
purul
discharg
cathet
insert
site
pretreat
diagnost
evalu
suspect
hai
includ
least
two
blood
cultur
eg
indwel
cathet
along
peripher
site
cerebrospin
fluid
csf
cultur
urin
cultur
isol
con
singl
blood
cultur
usual
interpret
contamin
definit
diagnosi
hai
due
bacteri
fungal
speci
requir
isol
organ
blood
anoth
normal
steril
bodi
site
fluid
except
fungi
aspergillu
zygomycet
caus
potenti
fatal
dissemin
multiorgan
infect
rare
isol
blood
use
serum
biomark
fungal
diseas
assay
neonat
requir
studi
viral
infect
suspect
presumpt
diagnosi
made
rapid
diagnost
test
eg
posit
direct
fluoresc
antibodi
dfa
test
adenoviru
herp
simplex
viru
enzym
immunoassay
eia
influenza
respiratori
syncyti
viru
rotaviru
polymeras
chain
reaction
test
definit
diagnosi
isol
viral
cultur
becom
avail
valid
test
bodi
fluid
blood
csf
nasal
wash
tracheal
secret
bronchoalveolar
lavag
fluid
stool
permit
rapid
viral
diagnosi
attempt
identifi
depend
serum
marker
diagnosi
sever
prognosi
somewhat
success
includ
use
complet
blood
cell
count
creactiv
protein
crp
variou
proinflammatori
cytokin
serum
hepcidin
procalcitonin
pct
level
two
metaanalysi
pct
show
potenti
use
diagnosi
lateonset
sepsi
one
studi
found
pct
accur
crp
level
studi
consist
result
empir
antimicrobi
therapi
suspect
hai
without
clinic
focu
neonat
guid
knowledg
distribut
part
ii
clinic
syndrom
cardin
featur
infecti
diseas
approach
diagnosi
initi
manag
confirm
sepsi
nec
result
show
decreas
allcaus
mortal
decreas
length
stay
studi
evalu
small
larger
clinic
trial
need
determin
use
adjunct
agent
may
promis
larger
multicent
trial
use
gmcsf
prophylaxi
lateonset
sepsi
neonat
younger
week
gestat
small
gestat
age
show
signific
differ
sepsisfre
surviv
review
data
studi
granulocyt
transfus
septic
neonat
demonstr
improv
outcom
situat
neutropen
deplet
marrow
storag
pool
associ
morbid
includ
fluid
overload
worsen
hypoxia
respiratori
distress
leukocyt
sequestr
lung
graftversushost
diseas
risk
transmiss
viral
infect
care
assess
risk
benefit
leukocyt
administr
requir
use
adjunct
therapi
remov
intravascular
cathet
constitut
optim
manag
bsi
occur
nevertheless
vital
import
cvc
critic
ill
neonat
must
acknowledg
especi
success
treatment
clabsi
situ
becom
common
bsi
occur
without
clabsi
differenti
two
condit
difficult
random
trial
guid
manag
clabsi
nicu
sever
larg
observ
cohort
studi
compar
outcom
lateonset
sepsi
neonat
cvc
treat
without
cvc
remov
data
suggest
manag
strategi
depend
pathogen
clinic
condit
infant
treatment
cvc
situ
attempt
antimicrobi
agent
administ
contamin
cathet
algorithm
shown
fig
provid
framework
manag
clabsi
neonat
evid
becom
avail
random
trial
sever
adjunct
therapi
investig
lateonset
sepsi
includ
immun
globulin
intraven
igiv
hematopoiet
growth
factor
ie
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
gmcsf
granulocyt
transfus
pentoxifyllin
igiv
gcsf
gmcsf
administr
granulocyt
transfus
evalu
cochran
databas
systemat
review
conclus
insuffici
evid
support
routin
use
treatment
neonat
sepsi
pentoxifyllin
also
review
cochran
databas
adjunct
antibiot
treatment
suspect
polymicrobi
infect
polymicrobi
bsi
neonat
account
case
lateonset
sepsi
usual
occur
later
monomicrobi
sepsi
neonat
sever
underli
condit
among
longerindwel
cvc
con
common
organ
recov
cultur
seen
combin
gramposit
gramneg
organ
prudent
remov
cvc
soon
possibl
case
polymicrobi
sepsi
likelihood
advers
outcom
focal
complic
increas
bsi
persist
neonat
although
uncertain
whether
focal
complic
caus
consequ
persist
bsi
imper
clinician
obtain
serial
blood
cultur
document
resolut
bsi
perform
thorough
diagnost
evalu
search
focal
complic
bsi
persist
bsi
persist
clinician
must
make
manag
decis
concern
time
cvc
remov
chang
antimicrobi
therapi
sever
case
report
success
treatment
persist
con
clabsi
cvc
situ
without
advers
consequ
ad
rifampin
standard
antistaphylococc
antimicrobi
therapi
pathogen
especi
candida
speci
may
continu
isol
blood
cultur
despit
prompt
remov
cvc
administr
antifung
therapi
one
seri
neonat
case
candidiasi
last
day
case
risk
focal
complic
invas
candidiasi
significantli
increas
case
persist
compar
nonpersist
bsi
vs
common
focal
complic
fungu
ball
uropathi
renal
infiltr
abscess
endocard
one
half
neonat
persist
candidiasi
focal
complic
chapman
faix
suggest
aggress
imag
focal
complic
reserv
case
blood
cultur
remain
posit
despit
sever
day
antifung
therapi
clinic
sign
suggest
focal
complic
noyola
associ
document
focal
complic
neonat
candidemia
includ
one
posit
blood
cultur
investig
recommend
renal
cardiac
ophthalmolog
diagnost
evalu
neonat
candidemia
exist
focal
complic
may
affect
durat
therapi
outcom
preval
persist
bsi
seri
case
bacteremia
one
nicu
case
seri
frequent
decis
treat
bacteri
bsi
cvc
situ
contribut
high
preval
persist
case
preval
focal
suppur
complic
ie
osteomyel
septic
arthriti
abscess
infect
thrombu
endocard
significantli
increas
durat
bsi
greater
persist
noncon
bsi
compar
persist
con
bsi
vs
aureu
caus
persist
noncon
bsi
case
focal
complic
studi
author
recommend
neonat
persist
bsi
undergo
extens
evalu
focal
complic
especi
endocard
osteomyel
soft
tissu
abscess
evalu
especi
import
case
persist
bsi
caus
aureu
enterobacteriacea
bacteremia
resolv
soft
tissu
abscess
sometim
suppur
phlebiti
bone
joint
infect
drain
intravascular
clot
dissolv
risk
factor
clabsi
extens
examin
includ
use
total
parenter
nutrit
mechan
ventil
previou
bsi
previou
exposur
thirdgener
cephalosporin
cohort
studi
monozygot
dizygot
prematur
infant
conclud
varianc
occurr
lateonset
sepsi
might
result
genet
factor
environment
factor
candida
speci
singlecent
retrospect
studi
case
report
failur
remov
cvc
soon
candida
sepsi
detect
neonat
associ
significantli
increas
mortal
rate
c
albican
sepsi
ie
casefat
risk
increas
number
need
harm
significantli
prolong
durat
candida
sepsi
regardless
candida
speci
ie
median
day
vs
day
find
confirm
retrospect
multicent
studi
elbw
infant
system
candidiasi
infecti
diseas
societi
america
idsa
guidelin
treatment
catheterrel
infect
guidelin
manag
candidiasi
nicu
patient
strongli
recommend
cvc
remov
soon
candida
sepsi
detect
feasibl
lumbar
punctur
dilat
retin
examin
perform
coagulaseneg
staphylococci
difficult
interpret
clinic
studi
con
clabsi
neonat
mani
studi
requir
singl
posit
blood
cultur
inclus
includ
mani
case
pseudobacteremia
seri
case
con
clabsi
least
two
posit
blood
cultur
investig
conclud
treatment
situ
often
could
success
observ
unclear
long
clinician
wait
abandon
steril
attempt
remov
cvc
karlowicz
colleagu
report
treatment
situ
vancomycin
success
case
con
clabsi
none
patient
con
bsi
day
institut
antibiot
therapi
resolut
cvc
remov
contrast
case
con
bsi
day
less
success
treat
without
cvc
remov
success
treatment
rate
decreas
bsi
persist
day
con
clabsi
persist
neonat
whose
cathet
vital
clinic
care
practic
administ
antibiot
treatment
cvc
day
perhap
long
day
special
circumst
never
beyond
day
persist
bacteremia
remov
cvc
although
use
antibiot
lock
therapi
day
combin
system
antibiot
treatment
treatment
con
clabsi
part
idsa
treatment
guidelin
shortand
longterm
cvc
role
vancomycin
lock
therapi
prevent
nicu
requir
studi
enterobacteriacea
although
enterobacteriacea
common
caus
lateonset
sepsi
data
limit
concern
clabsi
report
case
enterobacteriacea
clabsi
neonat
resolut
infect
report
case
use
gentamicin
tobramycin
without
cvc
remov
success
treatment
enterobacteriacea
bsi
day
durat
uncommon
without
remov
cvc
attempt
treat
enterobacteriacea
bsi
cvc
situ
associ
observ
increas
mortal
morbid
recurr
sever
thrombocytopenia
platelet
count
first
day
enterobacteriacea
bsi
resolv
cvc
remov
case
practic
remov
cvc
case
associ
sever
thrombocytopenia
enterobacteriacea
bsi
persist
day
commenc
appropri
antibiot
treatment
staphylococcu
aureu
adult
remov
cvc
advis
case
aureu
bsi
unless
compel
reason
conserv
cathet
publish
report
concern
aureu
clabsi
neonat
children
review
case
aureu
clabsi
patient
one
institut
includ
prematur
neonat
patient
complic
relat
infect
exclud
prolong
bacteremia
recurr
common
rate
complic
lower
among
patient
whose
cathet
remov
less
day
onset
infect
compar
whose
cathet
remov
remov
day
onset
data
treat
aureu
clabsi
situ
conflict
show
poor
success
case
treat
success
cvc
situ
show
resolut
mssa
bsi
within
hour
start
penicillinaseresist
penicillin
focal
complic
eg
soft
tissu
abscess
endocard
osteomyel
may
import
risk
factor
persist
aureu
bsi
retent
cvc
practic
use
cautiou
approach
remov
cvc
immedi
infect
persist
day
initi
appropri
antibiot
treatment
especi
sourc
aureu
infect
identifi
part
ii
clinic
syndrom
cardin
featur
infecti
diseas
approach
diagnosi
initi
manag
gg
found
decreas
rate
infect
infant
given
blf
compar
placebo
group
use
oral
lactoferrin
review
cochran
databas
conclud
evid
low
moder
qualiti
suggest
oral
lactoferrin
prophylaxi
decreas
lateonset
sepsi
preterm
infant
complet
sever
ongo
trial
may
improv
qualiti
evid
american
academi
pediatr
red
book
committe
infecti
diseas
said
use
fluconazol
prophylaxi
prevent
invas
candidiasi
elbw
infant
consid
nurseri
moder
high
rate
invas
candidiasi
infect
control
practic
optim
kaufman
colleagu
demonstr
signific
reduct
invas
fungal
diseas
elbw
infant
given
fluconazol
prophylaxi
placebo
vs
respect
level
invas
candidiasi
higher
nicu
center
nichd
nrn
time
strongest
effect
appear
occur
prophylaxi
target
highrisk
patient
birth
weight
less
g
use
cvc
may
reason
use
fluconazol
dose
mgkg
twice
per
week
intraven
central
peripher
access
longer
need
highrisk
popul
start
first
day
life
nystatin
prophylaxi
also
studi
although
extens
show
potenti
effect
highrisk
popul
may
increas
gastrointestin
side
effect
compar
fluconazol
use
probiot
nicu
controversi
probiot
use
studi
vari
probiot
consid
differ
strain
probiot
may
common
characterist
action
also
may
uniqu
properti
action
toward
specif
target
gener
difficult
metaanalysi
random
control
trial
enter
probiot
supplement
recommend
use
probiot
preterm
infant
suitabl
product
avail
benefit
reduct
death
nec
diseas
clear
inestig
one
multicent
random
control
trial
show
higher
preval
sepsi
periventricular
leukomalacia
among
infant
weigh
g
probiot
group
anoth
random
control
trial
show
increas
associ
vancomycinresist
enterococcu
colon
vlbw
infant
given
probiot
despit
studi
show
benefit
evid
infect
prevent
product
safeti
requir
elucid
univers
recommend
probiot
supplement
especi
regard
strain
use
refer
avail
onlin
wwwexpertconsultcom
manipul
central
line
increas
risk
clabsi
includ
placement
line
mainten
dress
repeat
entri
cvc
system
approach
minim
intervent
decreas
rate
clabsi
success
program
address
technic
contextu
factor
often
use
care
bundl
guidelin
bizzarro
cowork
perform
qualiti
improv
initi
design
reduc
nicu
infect
rate
implement
sever
intervent
use
multidisciplinari
approach
use
guidelin
cvc
care
intervent
associ
decreas
rate
clabsi
case
per
central
lineday
lateonset
sepsi
case
per
patientday
hand
decontamin
hcp
effect
mean
prevent
hai
often
overlook
perform
poorli
nicu
environ
activ
skin
contact
respiratori
care
diaper
chang
independ
associ
increas
hand
contamin
cdc
recommend
hcp
use
alcoholbas
hand
rub
rather
antimicrobi
soap
alcoholbas
hand
rub
excel
antimicrobi
spectrum
bacteria
fungi
virus
alcoholbas
hand
rub
also
rapid
speed
action
least
like
caus
hand
dermat
hcp
institut
hand
hygien
taskforc
includ
problembas
taskori
educ
program
help
hand
hygien
complianc
concurr
decreas
infect
rate
import
continu
staff
involv
ensur
success
use
chlorhexidin
glucon
chg
nicu
cvc
care
increas
one
survey
show
respond
use
chg
offlabel
use
approv
us
food
drug
administr
use
children
younger
month
age
data
support
use
chg
patient
bath
neonat
pediatr
popul
chg
antisepsi
part
central
venou
cathet
guidelin
unit
kingdom
sinc
evid
clinic
trial
lack
soothil
colleagu
great
ormond
street
hospit
gosh
children
report
profound
sustain
fall
clabsi
per
lineday
hematopoiet
stem
cell
transplant
pediatr
patient
profound
sustain
fall
clabsi
occur
chang
cvc
hub
antisepsi
isopropyl
alcohol
cvc
hub
antisepsi
chg
hub
scrub
ident
chg
isopropyl
alcohol
group
signific
reduct
clabsi
rate
like
associ
introduct
chg
cvc
hub
antisepsi
friction
hub
scrub
soothil
colleagu
also
report
cvc
hub
antisepsi
chg
associ
mark
fall
clabsi
rate
throughout
gosh
advantag
chg
cvc
hub
antisepsi
chg
cvc
hub
antisepsi
use
soothil
colleagu
gosh
chg
similar
effect
requir
one
half
time
chg
cvc
hub
antisepsi
take
second
ie
hub
scrub
follow
dri
time
compar
second
chg
cvc
hub
antisepsi
ie
hub
scrub
follow
dri
time
describ
chg
packag
insert
prematur
infant
requir
respiratori
enter
support
system
corticosteroid
h
block
agent
use
prevent
chronic
lung
diseas
enhanc
gastrointestin
function
respect
dexamethason
therapi
vlbw
infant
associ
increas
risk
lateonset
sepsi
use
h
block
agent
vlbw
infant
associ
higher
rate
nec
bsi
candidemia
avoid
use
dexamethason
h
block
agent
reduc
rate
lateonset
sepsi
human
milk
contain
sever
substanc
provid
benefici
effect
prematur
infant
includ
enhanc
innat
immun
enhanc
mucos
barrier
establish
full
enter
feed
human
milk
associ
lower
risk
lateonset
sepsi
elbw
infant
human
milk
found
reduc
develop
nec
sixfold
studi
vlbw
infant
receiv
compar
receiv
less
human
milk
first
day
life
use
bovin
lactoferrin
blf
also
studi
prevent
sepsi
italian
studi
group
neonat
infect
studi
effect
lactoferrin
without
probiot
lactobacillu
